* Avastin extends survival as second round treatment- study
* Boost after previous setbacks
ZURICH, Jan 26 (Reuters) - Patients with advanced colorectal cancer who received Roche's Avastin live longer when they also receive the drug as part of their second round of treatment, the Swiss drugmaker said on Thursday, citing a late-stage study.
Patients with metastatic colorectal cancer first treated with Avastin and standard chemotherapy before being given Avastin with a different chemotherapy after their disease had progressed lived significantly longer than those given only chemotherapy in the second-line setting, Roche said.
The news is likely to boost sentiment around the drug, which recently suffered a major setback when U.S. authorities decided to revoke their backing of its use in breast cancer.
Roche will submit the results of the ML 18147 study at an upcoming medical meeting.
In Europe, Avastin is currently approved in colorectal, lung, renal, breast cancer and it has just won approval in ovarian cancer. (Reporting by Katie Reid; Editing by Hans-Juergen Peters)